clinical failure analysis derived

{
  "input": {
    "type": "http",
    "method": "GET",
    "queryParams": {
      "lang": "en | es | fr | de | ja | zh | ko | pt | ar | hi (default: en)",
      "condition": "Disease — e.g. \"Alzheimer Disease\" | \"Sepsis\" | \"ALS\" | \"Depression\" | \"NASH\""
    }
  },
  "output": {
    "type": "json",
    "example": {
      "query_summary": {
        "condition": "Alzheimer Disease",
        "trials_analyzed": 78
      },
      "lessons_learned": [
        "Early intervention is critical — treat pre-symptomatic or MCI only",
        "Amyloid PET and CSF biomarkers required for enrollment (not just clinical diagnosis)",
        "CDR-SB global score now accepted primary endpoint by FDA (post-2018)",
        "ARIA management protocols must be pre-specified — not post-hoc",
        "Combination approaches (amyloid + tau + neuroinflammation) likely needed"
      ],
      "failure_taxonomy": {
        "wrong_endpoint": {
          "pct": 18,
          "examples": [
            "ADAS-Cog and MMSE insensitive to early disease changes; CDR-SB now standard"
          ],
          "key_trials": [
            "Multiple agents 2010-2020"
          ]
        },
        "safety_termination": {
          "pct": 8,
          "examples": [
            "ARIA (amyloid-related imaging abnormalities) from anti-amyloid antibodies; dose-limiting"
          ],
          "key_trials": [
            "Aducanumab Phase 3 dose arm"
          ]
        },
        "operational_failures": {
          "pct": 4,
          "examples": [
            "COVID-19 disruption, enrollment failures in rare AD subpopulations"
          ]
        },
        "wrong_patient_population": {
          "pct": 28,
          "examples": [
            "Treating symptomatic patients too late — amyloid deposited 10-15 years before symptoms"
          ],
          "key_trials": [
            "Bapineuzumab (mild-moderate vs. early)"
          ]
        },
        "wrong_target_or_hypothesis": {
          "pct": 42,
          "examples": [
            "Decades of amyloid-only focus; tau, neuroinflammation, synaptic loss all contributing to failure cascade"
          ],
          "key_trials": [
            "Solanezumab",
            "Verubecestat",
            "Atabecestat"
          ]
        }
      },
      "what_still_might_fail": [
        "Tau-targeting agents if amyloid clearance alone sufficient",
        "Agents tested in wrong disease stage despite lessons",
        "CNS inflammation approaches without biomarker stratification"
      ],
      "historical_success_rates": {
        "phase2_to_phase3_pct": 31,
        "phase3_to_approval_pct": 11,
        "vs_all_diseases_benchmark": "Alzheimer's has the lowest Phase 3 success rate of any major disease category (11% vs. 58% oncology, 67% hematology)",
        "overall_clinical_success_pct": 3.4
      },
      "successful_design_principles": "CLARITY-AD (lecanemab) and TRAILBLAZER-ALZ2 (donanemab) succeeded by: earlier disease staging, biomarker-confirmed enrollment, CDR-SB endpoint, adequate duration."
    }
  }
}